CliffBio
small molecule

ZIOPTAN

TAFLUPROST

Loss of exclusivityMay 2029latest FDA-listed patent expiry
CompanyThea →See this company's full patent-cliff portfolio

Drug detail

Brand nameZIOPTAN
Active ingredientTAFLUPROST
Strength0.0015%
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalFebruary 2012
Marketing statusRX

Listed patents

PatentExpiresType
10864159May 2029product
9999593May 2029product

More from Thea

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.